The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Hepatocellular Carcinoma.

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Esophageal Cancer.

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

Sacituzumab govitecan failed to improve overall survival in the EVOKE-01 trial, but was well tolerated with no new safety signals. Comprehensive genomic profiling is crucial to address testing ...

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and ...

The health technology assessment (HTA) agency said that while Trodelvy (sacituzumab govitecan) increases the time people have before their disease worsens and how long they live, "it is too ...

Gilead Sciences GILD announced that its first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy (sacituzumab govitecan-hziy), has been granted a second Breakthrough Therapy designation by ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...